First Trust Capital Management
TLSI icon

First Trust Capital Management’s TriSalus Life Sciences TLSI Stock Holding History

First Trust Capital Management’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-713,532
Closed -$7.08M – 356
2022
Q3 		$7.08M Buy
713,532
+644,740
+937% +$6.38M 0.33% 84
2022
Q2 		$677K Buy
68,792
+43,693
+174% +$429K 0.05% 295
2022
Q1 		$246K Buy
+25,099
New +$248K 0.03% 215

Other funds holding TLSI

Magnetar Financial
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Dark Forest Capital Management
Dark Forest Capital Management San Juan, Puerto Rico $1.55B AUM 23.63% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $128M AUM 19.21% 1-Year Est. Return
Meteora Capital
Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Boothbay Fund Management
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Virtu Financial
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

First Trust Capital Management's TLSI Position: Q4 2022 in Review

First Trust Capital Management sold out of TriSalus Life Sciences (TLSI) in Q4 2022, closing a stake of 713,532 shares — an estimated $7.08M sold.

First Trust Capital Management first reported a position in TLSI in Q1 2022 and held it in 3 quarters. The position peaked at $7.08M in Q3 2022. 9 funds tracked by Wall St. Rank hold TLSI as of Q4 2022.

  • First Trust Capital Management reported no remaining TriSalus Life Sciences position as of Q4 2022 after selling out during the quarter.
  • First Trust Capital Management sold 713,532 TriSalus Life Sciences shares in Q4 2022, an estimated $7.08M.
  • First Trust Capital Management first reported a position in TriSalus Life Sciences in Q1 2022 and held it in 3 quarters.
  • First Trust Capital Management's TriSalus Life Sciences position peaked at $7.08M in Q3 2022.
  • 9 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2022.

Based on First Trust Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.